Experiment Number: C55301B
Route: Gavage, IV
Species/Strain: Rat/F344/N

Toxicokinetics Data Summary
Test Compound: Pyridine
CAS Number: 110-86-1

Date Report Requested: 11/09/2016
Time Report Requested: 14:04:24
Lab: T.S.I. Mason Laboratories, Inc.

Male

	Treatment Groups (mg/kg)			
	5 [a]	**25 [a]**	**100 [a]**	**5 IV [a]**
C_{max} (ug/mL)	2.9	20.4	65.7	4.9
T_{max} (minute)	30.0	60.0	120.0	3.0
$t_{1/2}$ (minute)	73.0	710.0	1200.0	80.0
$t_{1/2(k01)}$ (minute)	30.0	16.0	21.0	
AUC_{0-t} (min*ug/mL)	1255.0 ± 46.0	12322.0 ± 171.0	50595.0 ± 118.0	1200.0 ± 94.0
F (fraction)	1.05 ± 0.09			

Experiment Number: C55301B
Route: Gavage, IV
Species/Strain: Rat/F344/N

Toxicokinetics Data Summary
Test Compound: Pyridine
CAS Number: 110-86-1

Date Report Requested: 11/09/2016
Time Report Requested: 14:04:24
Lab: T.S.I. Mason Laboratories, Inc.

	Female			
	Treatment Groups (mg/kg)			
	5	**25**	**100**	**5 IV**
C_{max} (ug/mL)	3.4	18.2	62.9	4.4
T_{max} (minute)	60.0	60.0	120.0	3.0
$t_{1/2}$ (minute)	120.0	650.0	1200.0	130.0
$t_{1/2(k01)}$ (minute)	35.0	32.0	20.0	
AUC_{0-t} (min*ug/mL)	1347.0 ± 58.0	12562.0 ± 356.0	51352.0 ± 1077.0	1185.0 ± 49.0
F (fraction)	1.14 ± 0.06			

LEGEND

Data are displayed as mean ± SEM

MODELING METHOD & BEST FIT MODEL

Calculated

ANALYTE

Pyridine

TK PARAMETERS

C_{max} = Observed or Predicted Maximum plasma (or tissue) concentration

T_{max} = Time at which C_{max} predicted or observed occurs

$t_{1/2}$ = $Lambda_z$ half-life, $t_{1/2}$, the terminal elimination half-life based on non-compartmental analysis

$t_{1/2(k01)}$ = Half-life of the absorption process to the central compartment

AUC_{0-t} = Area under the plasma concentration versus time curve, AUC, from time t_i (initial) to t_f (final), AUC_{last}

F = Bioavailability, absolute bioavailability

** END OF REPORT **